Education
About Us
Working with TipRanks
Follow Us
Bioventix PLC (GB:BVXP)
LSE:BVXP
BVXP Stock Chart & Stats
1800.00 p
56.00 p(1.70%)
At close: 4:00 PM EST
1800.00 p
56.00 p(1.70%)
Day’s Range― - ―
52-Week Range1,450.00 p - 3,020.00 p
Previous CloseN/A
Volume24.00
Average Volume (3M)7.85K
Market Cap
£78.37M
Enterprise Value69.37M
Total Cash (Recent Filing)£5.08M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)18.9
Beta0.34
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield8.33%
Share Statistics
EPS (TTM)0.72
Shares Outstanding5,224,860
10 Day Avg. Volume9,152
30 Day Avg. Volume7,851
Financial Highlights & Ratios
PEG Ratio-2.93
Price to Book (P/B)12.43
Price to Sales (P/S)10.95
P/FCF Ratio20.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.36
Revenue Forecast (FY)£12.50M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained very high net margins reflect durable pricing power of proprietary monoclonal antibodies and a royalty-driven business model. High margins provide structural capacity to fund R&D, pay dividends, and absorb volume volatility without immediate margin erosion.
Strong Cash ConversionNear-1.0 cash conversion indicates earnings reliably become cash, supporting consistent dividends, reinvestment, and low reliance on external funding. This trait underpins durable shareholder returns and resilience through cyclical dips in test volumes.
Conservative Balance SheetZero debt and very high ROE (mid-50% to ~70%) give the company financial flexibility to fund new antibody development, sustain payouts, or support customers. A debt-free balance sheet materially reduces refinancing and solvency risk over the medium term.
Bears Say
Recent Revenue & FCF SlowdownA decline in both revenue and free cash flow in 2025 signals waning placement momentum or lower test volumes. Because royalties scale with customer sales, sustained top-line softness could reduce recurring cash royalties and pressure future investment capacity.
Negative Revenue TrendMeasured negative revenue growth over the latest period points to structural demand or adoption headwinds. If new assay design-ins slow and legacy assay volumes stagnate, the company's royalty-led model may struggle to replace lost growth without new long-duration placements.
Geographic / Market PressureExposure to regional market weakness and major IVD customers concentrates risk: regulatory changes, slower Chinese volumes or customer-specific shifts can meaningfully reduce royalty streams. Geographic and customer concentration is a structural vulnerability.
Bioventix News
BVXP FAQ
What was Bioventix PLC’s price range in the past 12 months?
Bioventix PLC lowest share price was 1450.00 p and its highest was 3020.00 p in the past 12 months.
What is Bioventix PLC’s market cap?
Bioventix PLC’s market cap is £78.37M.
When is Bioventix PLC’s upcoming earnings report date?
Bioventix PLC’s upcoming earnings report date is Mar 30, 2026 which is in 16 days.
How were Bioventix PLC’s earnings last quarter?
Bioventix PLC released its earnings results on Oct 27, 2025. The company reported 0.72 p earnings per share for the quarter, missing the consensus estimate of 0.78 p by -0.06 p.
Is Bioventix PLC overvalued?
According to Wall Street analysts Bioventix PLC’s price is currently Overvalued.
Does Bioventix PLC pay dividends?
Bioventix PLC pays a Semiannually dividend of 80 p which represents an annual dividend yield of 8.33%. See more information on Bioventix PLC dividends here
What is Bioventix PLC’s EPS estimate?
Bioventix PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioventix PLC have?
Bioventix PLC has 5,224,860 shares outstanding.
What happened to Bioventix PLC’s price movement after its last earnings report?
Bioventix PLC reported an EPS of 0.72 p in its last earnings report, missing expectations of 0.78 p. Following the earnings report the stock price went down -15.699%.
Which hedge fund is a major shareholder of Bioventix PLC?
Currently, no hedge funds are holding shares in GB:BVXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bioventix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
GB:BVXP Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth £53.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.51%
12-Months-Change
Fundamentals
Return on Equity
66.44%
Trailing 12-Months
Asset Growth
-6.32%
Trailing 12-Months
Company Description
Bioventix PLC
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious disease, oncology, and miscellaneous indications. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in London, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Oxford BioDynamics
―
Fusion Antibodies Plc
―
4basebio UK Societas
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---